Loading provider…
Loading provider…
Hematology & Oncology Physician in Beverly Hills, CA
NPI: 1083610596Primary Employer
Cedars-Sinai Medical Care Foundation
cedars-sinai.org
HQ Phone
Get M.D. Dorothy's Phone Numberphone_androidMobile
Get M.D. Dorothy's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1989 - 2026
Cedars-Sinai Medical Center
Fellowship • Hematology and Medical Oncology
1992 - 1994
UCLA-VA Greater Los Angeles
Residency • Internal Medicine
1987 - 1990
David Geffen School of Medicine at UCLA
medschool.ucla.edu
Medical School
Until 1987
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 203 | 575 |
| 2 | 36415Insertion of needle into vein for collection of blood sample | 192 | 392 |
| 3 | 99213Established patient office or other outpatient visit, typically 15 minutes | 62 | 103 |
| 4 | 99205New patient office or other outpatient visit, typically 60 minutes | 35 | 35 |
| 5 | 99215Established patient office or other outpatient, visit typically 40 minutes | 26 | 44 |
Authors: Katherine Sanchez, Philomena Mcandrew, Laura Bennetts, Walter Urba, Isaac Kim, Maryliza El-Masry, David Page, Brie Chun, Anupama Acheson, Heather Mcarthur, Reva Basho, Alison Conlin
Journal: NPJ Breast Cancer
Publication Date: 2023-06-21
Authors: Hwangbo, Y, Kim, J H, Kim, S W, Park, Y J, Park, D J, Kim, S Y, Shin, C S, Cho, N H
Journal: Osteoporos Int
Publication Date: 2015-08-08
The aberrant fusion proteins PML-RARα and PLZF-RARα contribute to the overexpression of cyclin A1 in acute promyelocytic leukemia
Authors: Harold Koeffler
Publication Date: 2000-12
Lead Sponsor: Armando Giuliano
Intervention / Treatment: OTHER: Omit breast radiation
Lead Sponsor: Reva Basho
Collaborators: Merck Sharp & Dohme LLC, Seagen Inc.
Intervention / Treatment: DRUG: Trastuzumab, DRUG: Pembrolizumab, DRUG: Tucatinib
Lead Sponsor: Stephen Shiao
Collaborators: United States Department of Defense
Intervention / Treatment: DRUG: Pembrolizumab, RADIATION: RT Boost